Validation of the Modified Schein Dry Eye Symptom Questionnaire and Comparison With the Ocular Surface Disease Index

Jerry R. Paugh 1, Elaine Chen 1, Justin Kwan 2, Tiffany Nguyen 3, Alan Sasai 1, Melinda Thomas De Jesus 1,4, Andrew Loc Nguyen 5, Michael T. Christensen 6, and David Meadows 7

1 Southern California College of Optometry at Marshall B. Ketchum University, Fullerton, CA, USA
2 CooperVision Inc., Pleasanton, CA, USA
3 Private Practice, Dover, DE, USA
4 LensGen, Irvine, CA, USA
5 Department of Mathematics, California State University Fullerton, CA, USA
6 Southern College of Optometry, Memphis, TN, USA
7 Constellation Research, LLC, Colleyville, TX, USA

Correspondence: Jerry R. Paugh, Southern California College of Optometry at Marshall B. Ketchum University, 2575 Yorba Linda Blvd., Fullerton, CA 92831, USA. e-mail: jpaugh@ketchum.edu

Received: July 18, 2021
Accepted: November 23, 2021
Published: February 17, 2022

Keywords: dry eye; symptoms; validation; modified Schein questionnaire; Rasch analysis

Citation: Paugh JR, Chen E, Kwan J, Nguyen T, Sasai A, Thomas De Jesus M, Nguyen AL, Christensen MT, Meadows D. Validation of the modified Schein dry eye symptom questionnaire and comparison with the ocular surface disease index. Transl Vis Sci Technol. 2022;11(2):27, https://doi.org/10.1167/tvst.11.2.27

Purpose: This study evaluated the validity and diagnostic efficacy of a modified Schein dry eye questionnaire and compared it to the Ocular Surface Disease Index (OSDI).

Methods: The original Schein survey was modified to allow numerical scoring on a 0 to 24 scale and evaluated in prospective studies in normal and dry eye subjects. Receiver operating characteristic (ROC) analysis for test efficacy in aqueous deficient dry eye (ADDE) and evaporative dry eye (EDE) related to meibomian gland dysfunction was determined.

Results: Dry eye subtype, age and gender were statistically significant in explaining variation in modified Schein scores (n = 377; general linear model; all P values < 0.006) whereas for Ocular Surface Disease Index (OSDI) only age and gender were significant, but not dry eye subtype. The modified Schein ROC curve had an area under the curve (AUC) of 0.693 (95% confidence interval [CI], 0.635–0.753), with cutpoint of 7.5 (sensitivity of 0.75, specificity of 0.55). Similarly, the OSDI had an AUC of 0.685 (95% CI, 0.610–0.760), at a cutpoint of 10.4 (sensitivity of 0.75, specificity of 0.55). Modified Schein and OSDI correlated well (Pearson r = 0.81; P < 0.001). Symptom change for the modified Schein with artificial tear treatment was significant in EDE subjects (Dunnet's tests, P value < 0.001).

Conclusions: The modified Schein questionnaire is rapid to administer and score and compares well with the OSDI for test efficacy. Moreover, it differentiates normals from ADDE and EDE subtypes and is responsive to dry eye treatment. These attributes make the modified Schein survey an attractive dry eye symptom characterization instrument.

Translational Relevance: The modified Schein symptom survey, validated against clinical diagnosis and an existing survey, provides a new, efficacious diagnostic and treatment monitoring instrument in dry eye disease.

Introduction

Accurate and reliable measurement of the symptoms of ocular surface disease is important in the diagnosis of dry eye to determine prevalence through epidemiological studies and in monitoring treatment efficacy. Both the Dry Eye Workshop (DEWS) I and II working groups considered dry eye symptom questionnaires in their reports. They suggested that an
appropriate questionnaire should be sensitive enough to monitor disease progression or the effect of treatment over time\(^1\) and be able to establish a threshold of disease severity.\(^1\)

As part of the Salisbury Eye Evaluation (SEE) to determine prevalence of dry eye in a population-based sample, Schein and co-workers\(^3\) developed a dry eye symptom questionnaire that would be effective in detecting dry eye symptoms but that was efficient because of the large population to be surveyed. These authors began with a draft version and then refined and validated it using the specific likelihood ratio and latent class analysis in a clinic-based population of defined dry eye subtypes that included aqueous-deficient dry eye (ADDE) and evaporative dry eye (EDE) patients, and normals (n = 90 total subjects). The optimization process left six questions relating to the frequency of the most common dry eye symptoms encountered in their sample.\(^3\) This questionnaire has been labeled the SEE survey or is known informally as the Schein questionnaire.

The Schein instrument is very rapid to administer, \(~1\) minute, yet it occurred to us that further optimization might be desirable. We added a new response category of “never” to the existing options of rarely, sometimes, often, or all of the time. Moreover, we added numeric values to the responses to allow a semicontinuous reporting paradigm that could establish simple cutpoints to suggest whether respondents were likely to suffer from dry eye and to correlate to severity (Fig. 1).

The purpose of this investigation was to validate the modified Schein dry eye questionnaire against clinical diagnosis and to use a cross-validation method of data-splitting to establish a scale cutpoint and levels of test efficacy. Rasch analysis was used for survey validation by assessing the psychometric properties of the six questionnaire items. Further goals were to evaluate instrument repeatability and sensitivity to treatment change and to provide comparative data using the Ocular Surface Disease Index (OSDI).

### Materials and Methods

The modified Schein and OSDI questionnaires were evaluated for test efficacy in five prospective dry eye studies; of which a major aim was questionnaire validation and test efficacy in identifying dry eye disease. All studies used similar inclusion and exclusion criteria (see below) and used the same testing methods and criteria to assign the subjects as normal or dry. The combined data included normals, ADDE, and those with evaporative dry eye related to meibomian gland dysfunction (EDE). No subjects with blepharitis were included.

The total data set represented 377 unique subjects, of which a subset had repeatability data available within one week of the initial administration under conditions matching the initial survey. The use of the questionnaire to track treatment progress stemmed from a study of mid-viscosity artificial tears in dry eye subjects over a six-month treatment period.

The treatment monitoring study was a prospective, randomized (for artificial tear) masked parallel group investigation involving two mid-viscosity artificial tears. There was no control arm since two treatments for EDE related to meibomian gland dysfunction were investigated. Clinical trial registration number was NCT01207752 (ClinicalTrials.gov). The tears were either a propylene glycol 0.6% wt/vol (active) hp-guar-based and mineral oil (inactives) formulation (Systane Balance; Alcon Laboratories, Ft. Worth, TX, USA), or a carboxymethylcellulose (CMC) 0.5% (active) glycerin formulation (Refresh Optive; Allergan Inc., Irvine, CA, USA). Subjects continued their entering dry eye therapy and dosed the artificial tears four times per day every day for six months.

The study population was a clinic-based sample drawn from optometric and ophthalmologic academic centers, the Southern California College of Optometry at Marshall B. Ketchum University and the Gavin Herbert Eye Institute at the University of California at Irvine. The study was approved by the institutional review boards of both institutions and adhered to the tenets of the Declaration of Helsinki. Subjects provided written informed consent and signed Health Insurance Portability and Accountability Act authorizations before study participation.

Major **inclusion** criteria included subjects without dry eye or with either ADDE or EDE, age greater than 18 years, and best-corrected visual acuity of 20/40
or better at distance. Major exclusion criteria included blepharitis,\textsuperscript{4,5} uncontrolled systemic disease, diabetes, contact lens wear, prior keratorefractive surgery or enhancement within 12 months of assessment, active ocular infection or non-dry eye inflammation, and use of tear-influencing medications such as antihistamines unless the dosing regimen had been consistent for at least 30 days.

All subjects were evaluated using a consistent protocol. However, no symptom scores were used in this classification to qualify the subjects as dry or normal, only the objective measures of corneal and conjunctival staining, tear stability, and the dry eye subtype evaluations. Using the test under consideration to classify study subjects induces selection bias, which potentially overestimates test sensitivity and specificity.\textsuperscript{6}

Tear breakup time (TBUT) was assessed using liquid sodium fluorescein (2.0 μL of 1.0% wt/vol, instilled using a micropipette, with a yellow filter to enhance dark spot observation) because noninvasive methods were not available. The subject blinked naturally three times\textsuperscript{2} and the mean of three measurements recorded. Subjects were considered to have dry eye disease if the mean TBUT was ≤ 6.0 seconds\textsuperscript{7} or Level 2 severity.

Immediately after TBUT, within four to eight minutes,\textsuperscript{5} corneal staining was assessed with use of the yellow barrier filter. Conjunctival staining was assessed using lissamine-impregnated strips, wetted with nonpreserved saline solution that was allowed to soak the strip for at least five seconds\textsuperscript{2} to fully elute the dye. Staining was estimated for six zones for each eye; both corneal and conjunctival staining were quantified using the NEI scale.\textsuperscript{9} Subjects were considered dry if the corneal and conjunctival total staining score was > 6.0 on the 0–33 total NEI scale (Level 2 or greater\textsuperscript{10}). ADDE was assigned if the subject was dry by TBUT and staining, and the Schirmer I test without anesthesia was ≤ 5.0 mm, as recommended by several consensus groups.\textsuperscript{8,10,11}

To assign the EDE subtype, assuming a dry condition based on tear stability and staining, subjects had to exhibit greater than or equal to Grade 1.0 secretion quality\textsuperscript{13} as an average grade across the entire lower eyelid using a cotton-tipped applicator (Q-tip) to gently express the glands. The EDE subjects had to have a Schirmer I test > 5.0 mm wetting in five minutes. Symptoms were assessed with the Schein questionnaire,\textsuperscript{13} modified with numerical scores (described below) the OSDI, but the symptom data were not used to characterize the subjects as dry or normal to avoid selection bias.

The Modified Schein Survey

The symptomatology instrument originated from the development work of Schein and co-workers\textsuperscript{3} Six questions were selected by Schein et al.,\textsuperscript{3} following evaluation of a larger preliminary battery of 12 questions and responses from diagnosed dry eye patients. The final questions were as follows:

- Do your eyes ever feel dry?
- Do you ever feel a gritty or sandy sensation in your eye?
- Do your eyes ever have a burning sensation?
- Are your eyes ever red?
- Do you notice much crusting on your lashes?
- Do your eyes ever get stuck shut in the morning?

These questions were used in the present study to grade symptoms using a slight modification of the scale: “never” was added, and ordinal grades were assigned to the possible answers (“never” = Grade 0, “rarely” = Grade 1, “sometimes” = Grade 2, “often” = Grade 3, and “all of the time” = Grade 4; see Fig. 1). The questionnaire provided a total numerical score (maximum of 24 points if severe symptomatology) that could be used to correlate against signs.

The modified questionnaire was validated against clinical diagnosis, the OSDI validated instrument, and using Rasch analysis. A total of 377 useable charts were available and composed of normals (non-dry eye individuals) and either ADDE or EDE dry eye subtypes.

Statistical Analysis

A univariate general linear model (GLM; Minitab 18) and analysis of variance (ANOVA) were used for each questionnaire (modified Schein and OSDI) to determine factor effects of age, sex, and dry eye subtype. The OSDI data were log-transformed before analysis with the GLM due to non-normal residuals and nonconstant variance. Significant factors for dry eye subtype were compared using Tukey’s pairwise comparisons.

Data splitting\textsuperscript{14} was used as a cross-validation method to determine a Receiver Operating Characteristic (ROC) curve (R version 3.6.1) and scale cutpoint that optimized sensitivity and specificity, that was subsequently tested for predictive accuracy. Approximately two-thirds of the data were used for model-building, with the remainder available for model-checking.\textsuperscript{14}
Modified Schein Dry Eye Questionnaire Validation

Efficacy in Dry Eye Diagnosis: Modified Schein and OSDI

The modified Schein data were split, with approximately two-thirds randomly selected for model building and the remainder for model checking (predictive accuracy vs. clinical subtype assignment). Thus 85 normals, 26 ADDE and 164 EDE subjects’ data were used for model building. The cutpoint data are presented in Table 1. The area under the receiver operating characteristic curve (AUC) was 0.694 (95% CI, 0.626–0.763), demonstrating reasonable discrimination. A best-balance cutpoint of 7.5 (0–24 scale) provided a sensitivity of 0.74 (95% CI, 0.68–0.80) and specificity of 0.54 (95% CI, 0.43–0.65). This specificity is little better than chance, suggesting that healthy patients might be considered as having dry eye using a cutpoint of 7.5. In the model-checking data set, this cutpoint correctly predicted 58% of normals and 79% of the combined dry eye subjects.

We further examined test efficacy, using all available normal and dry eye data, for the entire sample and for the specific ADDE and EDE subtypes. These data are presented in Table 2 and Figure 2 and demonstrate AUCs similar to the model-building data set and the same optimum cutpoint (meaning the best balance of sensitivity and specificity) in the subanaly-

### Table 1. Cutpoints for Schein Model-Building Data*

| Schein Cutpoint (0–24 Scale) | Sensitivity (95% CI) | Specificity (95% CI) |
|-----------------------------|----------------------|----------------------|
| 5.5                         | 0.87 (0.82–0.92)     | 0.42 (0.32–0.52)     |
| 6.5                         | 0.82 (0.77–0.87)     | 0.49 (0.38–0.60)     |
| 7.5†                        | 0.74 (0.68–0.80)     | 0.54 (0.43–0.65)     |
| 8.5                         | 0.67 (0.60–0.74)     | 0.55 (0.44–0.66)     |
| 9.5                         | 0.56 (0.49–0.63)     | 0.64 (0.54–0.74)     |

* n = 85 normals and 189 drys (ADDEs and EDEs combined).
† Optimum balance of sensitivity and specificity.
Table 2. Total Sample and Subtype Analyses for Modified Test Efficacy

| Sample    | Normals | Dry Eye Disease | AUC (95% CI) | Cutpoint | Sensitivity (95% CI) | Specificity (95% CI) |
|-----------|---------|----------------|-------------|----------|----------------------|----------------------|
| All Subjects | 118     | 259            | 0.693 (0.635–0.753) | 7.5      | 0.75 (0.70–0.80)     | 0.55 (0.46–0.64)     |
| ADDEs      | 118     | 36             | 0.719 (0.630–0.809) | 7.5      | 0.81 (0.68–0.94)     | 0.55 (0.46–0.64)     |
| EDEs       | 118     | 223            | 0.689 (0.628–0.750) | 7.5      | 0.74 (0.68–0.80)     | 0.55 (0.46–0.64)     |

*Best balance of sensitivity and specificity.

Figure 2. ROC curves for normals (non-dry eye subjects) versus combined ADDE and EDE subtypes.

Table 3. Total Sample and Subtype Analyses for OSDI Test Efficacy

| Sample    | Normals | Dry Eye Disease | AUC (95% CI) | Cutpoint | Sensitivity (95% CI) | Specificity (95% CI) |
|-----------|---------|----------------|-------------|----------|----------------------|----------------------|
| All subjects | 88      | 118            | 0.685 (0.610–0.760) | 10.4     | 0.75 (0.68–0.83)     | 0.55 (0.45–0.65)     |
| ADDEs      | 88      | 21             | 0.764 (0.669–0.860) | 13.1     | 0.81 (0.64–0.98)     | 0.64 (0.54–0.74)     |
| EDEs       | 88      | 97             | 0.668 (0.589–0.746) | 10.2     | 0.74 (0.65–0.83)     | 0.51 (0.41–0.61)     |

*Best balance of sensitivity and specificity.

Treatment Efficacy

The modified Schein scores were monitored in a six-month, randomized, subject-masked treatment trial of mid-viscosity artificial tears dosed four times per day in EDE related to meibomian gland dysfunction subjects. Baseline modified Schein scores were within the dry eye range according to the current cutpoint of 7.5, and not different for the two formulations (10.9 ± 4.3 and 10.2 ± 3.2, respectively, for propylene glycol-hp-guar score and CMC 0.5%; P = 0.398, 95% CI for difference −1.037 to 2.571; two-sample t-test). The propylene glycol-hp-guar arm enrolled n = 35 subjects to start and completed 33 subjects. The CMC 0.5% arm enrolled n = 34 subjects and completed 26. The modified Schein scores decreased to 6.97 ± 4.2 (n = 33) and 7.92 ± 3.7 (n = 26), respectively, for propylene glycol-hp-guar and CMC 0.5% at six months. The changes from baseline were significant for both artificial tears (propylene glycol-hp-guar, P < 0.001; 95% CI, −5.14 to −2.46; CMC 0.5%, P = 0.001; 95% CI −3.61 to −0.733, adjusted P values, Dunnett’s simultaneous tests). The symptom reductions occurred with improvements in TBUT and ocular surface staining for both artificial tears.

Repeatability

Fifty-seven subjects (normals, combined with both dry eye subtypes) provided repeatability scores using the modified Schein survey within one week and under similar conditions and time of day as the initial administration. There were nine normals, eight ADDEED, and 40 EDED subjects. Mean/Median
Figure 3. Bland Altman plot of modified Schein repeatability. The mean difference is very small, demonstrating little bias of repeated scores.

(±SD/interquartile range)–modified Schein values were 11.0/11.0 (3.8/8–13) and 10.3/10.0 (3.4/8–13) for the first and repeat administrations, respectively. These were statistically different (P = 0.033; 95% CI, 0.052 to 1.262, paired t-test) but not clinically different responses.

The intraclass correlation coefficient was 0.78, considered good reliability (95% CI, 0.65–0.86; R software, model = one-way, type = consistency). The Bland Altman analysis is depicted in Figure 3.

Rasch Analysis

Detailed Schein data (i.e., individual item scores for each subject from each of the six symptom items) were available for 108 normal and dry eye subjects who all had been evaluated using the standard battery of dry eye tests as above). The Rasch model parameters are summarized in Table 4, and the modified Schein person-item map is presented in Figure 4.

Table 4. Rasch Model Parameters

| Item                                                                 | INFIT* |   | OUTFIT |   |
|---------------------------------------------------------------------|--------|---|--------|---|
|                                                                     | MNSQ   | ZSTD | MNSQ   | ZSTD |
| 1. Do your eyes ever feel dry?                                      | 0.59   | −3.5| 0.58   | −3.5|
| 2. Do you ever feel a gritty or sandy sensation in your eye?        | 1.00   | 0.1 | 0.97   | −0.1|
| 3. Do your eyes have a burning sensation?                           | 0.84   | −1.2| 0.82   | −1.3|
| 4. Are your eyes ever red?                                          | 1.07   | 0.6 | 1.02   | 0.2 |
| 5. Do you notice much crusting on your lashes?                       | 1.22   | 1.4 | 1.18   | 1.1 |
| 6. Do your eyes get stuck shut in the morning?                       | 1.59   | 3.1 | 1.32   | 1.2 |

*INFIT and OUTFIT statistics have expectation 1.0 and range from 0 to infinity. MNSQ values of 0.6 to 1.4 are considered reasonable for a rating scale/survey. ZSTD is the standard deviation of the fit parameters.

Correlation

In 206 subjects, both normal and dry eye disease, for which both questionnaires were administered concurrently, the Pearson correlation coefficient was 0.81 (95% CI, 0.76–0.86; P < 0.001), indicating an excellent relationship. Figure 5 presents the scatterplot.

Correlation analysis was carried out for modified Schein versus the clinical parameters of TBUT, NEI stain (0–33 scale), Schirmer I, tear meniscus height (mm), white-light interferometry (central cornea, Yokoi scale), meibomian gland expression (0–3 scale) and lower eyelid meiboscopy. Several clinical parameters demonstrated significant correlations versus the modified Schein score (i.e., P < 0.05), but only fluorescein breakup time (Pearson’s r = −0.303 [95% CI −0.392 to −0.208]; P < 0.001) rose to the level...
Modified Schein Person-Item Map

INPUT: 108 Persons 6 Items  MEASURED: 108 Persons 6 Items  5 CATS  1.0.0

| Persons with more symptoms | Items that are less frequently reported. |
|---------------------------|------------------------------------------|
| 3                         |                                          |
| 2                         | ItemQ6                                   |
| 1                         | ItemQ5                                   |
|                            | ItemQ2 ItemQ3                            |
|                            | ItemQ4                                   |
|                            | ItemQ1                                   |
|                            |                                          |
| -1                        |                                          |
| -2                        |                                          |
| -3                        |                                          |
| -4                        |                                          |
| -5                        |                                          |

Each '#' is 2 subjects.

Figure 4. The Person–Item map demonstrates a broad spread for the six symptom items, frequent reports of dryness, and infrequent reports of eyes stuck shut.
of a fair level of association ($r$ value $0.25–0.50$; Dawson and Trapp\textsuperscript{20}).

**Discussion**

This investigation involved further development of a previously validated dry eye symptomatology questionnaire, and validation in the absence of selection bias. Changes were made to the original Schein instrument in an effort to provide quantitation (using an ordinal scale) for individual questions and a total score (a semi-continuous scale, $0–24$) to allow diagnosis of both dry eye subtypes compared to non-dry eye individuals, as well as provide the opportunity for use as a quantitative monitoring tool.

Rasch analysis can be used for survey development to analyze individual items for optimization by eliminating those that do not well-reflect the underlying trait.\textsuperscript{15,21} In the present study, the Schein questionnaire was previously validated in the major dry eye subtype groups\textsuperscript{3} so in this case Rasch analysis provides a snapshot of the psychometric behavior of the modified questionnaire. The Rasch results suggest (Fig. 4 and Table 4) that all six symptom queries well-reflect the symptoms of dry eye disease. MNSQ values of 0.6 to 1.4 are considered reasonable for a survey instrument\textsuperscript{22} and all six items fall within that range. Furthermore, the ZSTDs, while borderline for “dryness” and “stuck shut in the morning,” suggest that the dryness symptom is overly predictive and perhaps underrepresented for stuck shut due to the exclusion of blepharitis subjects from this sample. The symptom capture for dryness is part of nearly all major dry questionnaires and should be retained.

We validated the modified Schein survey against clinical diagnosis and found that it well-separates non-dry eye persons from both dry eye subtypes (general linear model and Tukey comparisons). Moreover, it provides reasonable repeatability under consistent conditions; combined normal and dry eye subject score means for two visits of 11.0 and 10.3, respectively ($n = 57$), which was statistically, but not clinically significant. Modified Schein scores diminished with artificial tear treatment in EDE subjects, mirroring other clinical sign reductions, demonstrating usefulness in dry eye treatment trials. The modified Schein instrument also demonstrates concurrent validity when compared to the OSDI (Fig. 5).

ROC analysis suggests that the modified Schein questionnaire demonstrates acceptable discrimination, with AUCs ranging to 0.719 from 0.689 (Table 2 and Fig. 2).\textsuperscript{16} The cutpoints for normals versus combined dry eye subtypes and for normals versus individual subtypes were consistent at 7.5 on the 0 to 24 scale. This cutpoint resulted in test sensitivity of 0.74 or greater (Table 2), which is considered effective for dry eye diagnosis.\textsuperscript{10}

ROC analysis was also investigated for the OSDI, for normals vs. both dry eye subtypes and individually for the subtypes (Table 3). AUCs were similar to those for the modified Schein (0.668 to 0.764), with the greater AUC and cutpoint of $\sim 13$ occurring for the ADDE subtype. This may be a result of the generally greater severity of the ADDE dry eye subtype, although we did not quantify severity herein. The AUCs found in our study for OSDI are slightly greater, but similar to those reported by Yazdani et al.\textsuperscript{23} in a large study of normals and dry eye subjects analyzed using varying clinical cutoffs. Wang et al.\textsuperscript{24} also found a modest AUC for the OSDI and test sensitivity and specificity, similar to our results. Taken together, the evidence from these several studies suggests that symptoms alone are insufficient to accurately diagnose dry eye, and that additional clinical tests are necessary.

The TFOS DEWS II reports reviewed the currently available dry eye symptom questionnaires for domains sampled and utility (e.g., whether useful for epidemiological or clinical studies, Table 6; TFOS DEWS II Epidemiology report\textsuperscript{25}), and for screening criteria and validation methods (Table 2; TFOS DEWS II Diagnostic methodology report\textsuperscript{2}). Modification of the Schein questionnaire (labeled “SEE” as used in the Salisbury Eye Evaluation study\textsuperscript{3}) has allowed the instrument to become practical for clinical studies through dry eye discrimination and sensitivity to treatment. Similar
surveys include the Ocular Comfort Index, SPEED, OSDI, and DEQ-5 instruments, with these latter two recommended for use by the DEWS II diagnostic methodology report.\(^2\)

The Ocular Comfort Index was psychometrically developed and validated using Rasch analysis\(^15\) but is not referenced frequently in the literature. Wang et al.\(^24\) have recently assessed diagnostic efficacy for the SPEED, OSDI and DEQ-5 surveys in normal and dry eye subjects (unspecified with regard to dry eye subtype). Of these, only OSDI approached the test sensitivity level of 0.70, considered adequate for a dry eye diagnostic test.\(^10\) Not reaching diagnostic AUC or sensitivity levels were DEQ-5 and SPEED.\(^24\)

In contradistinction, Ngo et al.\(^26\) validated the SPEED survey with Rasch analysis and in an efficacy study found high AUCs for SPEED (0.928) and OSDI (0.970). Several studies, including the present investigation, have found lesser efficacy for OSDI in diagnosing dry eye.\(^23,24\) The contrasting efficacy results may be due to study sample size or entry criteria differences. The modified Schein questionnaire offers several advantages over existing questionnaires and has several limitations.

The instrument is extremely efficient, taking approximately one to two minutes to answer and to score. It has the major advantage that it is not protected by copyright, which can inhibit the use of questionnaires such as the DEQ-5 and the OSDI. The copyright inhibition can entail outright refusal for use of the OSDI in studies of competitor dry eye product companies or can entail a sizeable fee requirement annually for use of the questionnaire. To achieve universal acceptance and adoption, tests are needed for dry eye diagnosis and monitoring that are not only valid and efficacious but widely available without restriction.

The modified Schein instrument only surveys frequency of dry eye symptoms, and not their intensity, occurrence relative to time of day, nor vision-, or etiological components. These aspects of dry eye symptomatology may be important to dry eye sufferers' quality of life and should be incorporated into patient reported outcomes. Future research should examine the inter-laboratory reproducibility of the modified instrument and be examined in a treatment trial with a placebo control because our study did not include this. Additional investigation is needed to determine the meaningful clinical important difference in a large treatment trial,\(^17,27\) and to determine whether the modified Schein scale can be used to classify subjects as having mild, moderate or severe dry eye severity beyond the 7.5 scale cutpoint.

In summary, the modified Schein instrument is valid and differentiates normal from dry eye persons. It is clinically repeatable under stable conditions and has the ability to monitor dry eye treatment in concert with other clinical indicators. The consistent diagnostic cutpoint is 7.5 on the 0 to 24 scale. The modified Schein survey demonstrates similar test efficacy in dry eye diagnosis yet is more rapid to administer and score compared to the OSDI. It has promise for an effective screening questionnaire and in the symptom assessment as part of the larger battery of dry eye tests.

### Acknowledgments

Supported in part by an Investigator Initiated Trial grant from Alcon Laboratories 10306923 (J.R.P.).

Presented in part at the American Academy of Optometry Annual Meeting, October 2019, Orlando, Florida, USA.

Disclosure: J.R. Paugh, None; E. Chen, None; J. Kwan, Coopervision Inc. (E); T. Nguyen, None; A. Sasai, None; M. Thomas De Jesus, LensGen (E); A.L. Nguyen, None; M.T. Christensen, None; D. Meadows, None

### References

1. Smith JA, Albietz J, Begley C, et al. The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye Workshop. *Ocul Surf*. 2007;5:27–41.
2. Wolffsohn JS, Arita R, Chalmers R, et al. TFOS DEWS II Diagnostic Methodology report. *Ocul Surf*. 2017;15:539–574.
3. Schein OD, Tielsch JM, Munoz MS, Bandeen-Roche K, West S. Relation between signs and symptoms of dry eye in the elderly. *Ophthalmology*. 1997;104:1395–1401.
4. Nelson JD, Shimazaki J, Benitez-del-Castillo JM, Craig JP, McCulley JP, Den S, Foulks GN. The International Workshop on Meibomian Gland Dysfunction: report of the Definition and Classification Subcommittee. *Invest Ophthalmol Vis Sci*. 2011;52:1930–1937.
5. Sung J, Wang MTM, Lee SH, et al. Randomized double-masked trial of eyelid cleansing treatments for blepharitis. *Ocul Surf*. 2018;16:77–83.
6. Bron AJ, Abelson MB, Ousler G, et al. Methodologies to diagnose and monitor dry eye disease: report of the diagnostic methodology subcommittee of the International Dry Eye Workshop. *Ocul Surf*. 2007;5:108–152.
7. Paugh JR, Tse J, Nguyen T, et al. Efficacy of the fluorescein tear breakup time test in dry eye. *Cornea*. 2020;39:92–98.
8. Whitcher JP, Shiboski CH, Shiboski SC, et al. A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjogren's Syndrome International Registry. *Am J Ophthalmol*. 2010;149:405–415.
9. Lemp M. Report of the National Eye Institute/Industry workshop on clinical trials in dry eyes. *CLA O J*. 1995;21:221–232.
10. Tomlinson A, Bron AJ, Korb DR, et al. The International Workshop on Meibomian Gland Dysfunction: report of the Diagnosis Subcommittee. *Invest Ophthalmol Vis Sci*. 2011;52:2006–2049.
11. Akpek EK, Amescua G, Farid M, et al. Dry eye syndrome preferred practice pattern. *Ophthalmology*. 2019;126:P286–P334.
12. Fouks GN, Bron AJ. Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification and grading. *Ocul Surf*. 2003;1:107–126.
13. Bandeen-Roche K, Munoz B, Tielsch JM, West SK, Schein OD. Self-reported assessment of dry eye in a population-based setting. *Invest Ophthalmol Vis Sci*. 1997;38:2469–2475.
14. Kutner MH, Nachtsheim CJ, Neter J, Li W. *Applied Linear Statistical Models*. 5th ed. Boston: McGraw-Hill Irwin; 2005.
15. Johnson ME, Murphy PJ. Measurement of ocular surface irritation on a linear interval scale with the ocular comfort index. *Invest Ophthalmol Vis Sci*. 2007;48:4451–4458.
16. Hosmer DW, Lemeshow S. Assessing the fit of the model. In: *Applied Logistic Regression*. New York: John Wiley & Sons, Inc.; 2000:143–202.
17. Miller KL, Walt JG, Mink DR, et al. Minimal clinically important difference for the ocular surface disease index. *Arch Ophthalmol*. 2010;128:94–101.
18. Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. *J Chiropr Med*. 2016;15:155–163.
19. Hosseini K, Bourque LB, Hays RD. Development and evaluation of a measure of patient-reported symptoms of blepharitis. *Health Qual Life Outcomes*. 2018;16:1–6.
20. Dawson B, Trapp RG. Summarizing data & presenting data in tables & graphs. In: *Basic and Clinical Biostatistics*. New York: McGraw Hill; 2004:48–50.
21. Paugh JR, Kwan J, Christensen M, Nguyen AL, Senchyna M, Meadows D. Development of a Meibomian gland dysfunction-specific symptom questionnaire. *Eye Contact Lens*. 2018;44:6–14.
22. Wright BD, Linacre JM. Reasonable mean-square fit values. *Rasch Meas Trans*. 1994;8:370.
23. Yazdani M, Chen X, Tashbayev B, et al. Evaluation of the ocular surface disease index questionnaire as a discriminative test for clinical findings in dry eye disease patients. *Curr Eye Res*. 2019;44:941–947.
24. Wang MTM, Xue AL, Craig JP. Comparative evaluation of 5 validated symptom questionnaires as screening instruments for dry eye disease. *JAMA Ophthalmol*. 2019;137:228–229.
25. Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II Epidemiology Report. *Ocul Surf*. 2017;15:334–365.
26. Ngo W, Situ P, Keir N, Korb D, Blackie C, Simpson T. Psychometric properties and validation of the Standard Patient Evaluation of Eye Dryness questionnaire. *Cornea*. 2013;32:1204–1210.
27. Hwang CJ, Ellis R, Davis RM, Tolleson-Rinehart S. Determination of the minimal clinically important difference of the University of North Carolina Dry Eye Management Scale. *Cornea*. 2017;36:1054–1060.